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Themicroneutralization assay is commonly used to detect antibodies to influenza virus, andmultiple protocols are used world-
wide. These protocols differ in the incubation time of the assay as well as in the order of specific steps, and even within protocols
there are often further adjustments in individual laboratories. The impact these protocol variations have on influenza serology
data is unclear. Thus, a laboratory comparison of the 2-day enzyme-linked immunosorbent assay (ELISA) and 3-day hemaggluti-
nation (HA) microneutralization (MN) protocols, using A(H1N1)pdm09, A(H3N2), and A(H5N1) viruses, was performed by the
CONSISE LaboratoryWorking Group. Individual laboratories performed both assay protocols, on multiple occasions, using
different serum panels. Thirteen laboratories from around the world participated. Within each laboratory, serum sample titers
for the different assay protocols were compared between assays to determine the sensitivity of each assay and were compared
between replicates to assess the reproducibility of each protocol for each laboratory. There was good correlation of the results
obtained using the two assay protocols in most laboratories, indicating that these assays may be interchangeable for detecting
antibodies to the influenza A viruses included in this study. Importantly, participating laboratories have aligned their methodol-
ogies to the CONSISE consensus 2-day ELISA and 3-day HAMN assay protocols to enable better correlation of these assays in
the future.
Following infectionwith influenza viruses,most people developantibodies specific to the infecting virus that can be measured
by serological assays. These antibodies can be detected in the ma-
jority of people 2 to 3 weeks after symptom onset and can persist
formonths (1–4). Thus, serology can confirmpast infection in the
absence of clinical symptoms or virological data, detecting most
symptomatic and asymptomatic infections (5).
In 2011, an international partnership termed CONSISE (the
Consortium for the Standardization of Influenza Seroepidemiol-
ogy) was created in recognition of a need identified during the
2009 pandemic for timely seroepidemiological data to better esti-
mate pandemic virus infection severity and attack rates and to
inform policy decisions. CONSISE is comprised of individuals
from various organizations, with free membership. The activities
of CONSISE are performed by two interlinked working groups,
the Laboratory Working Group and the Epidemiology Working
Group, and a Steering Committee. The focus of the Laboratory
Working Group is to improve serological assay comparability and
standardization through consensus assay development, compara-
tive laboratory testing, and quality assurance (6) (https://consise
.tghn.org).
The main serological assays to detect antibodies to influenza
virus are the hemagglutination (HA) inhibition (HI) assay and the
microneutralization (MN) assay. The HI assay detects antibodies
that block the influenza virus hemagglutinin binding to sialic ac-
id-linked residues on red blood cells (RBC), while the MN assay
detects functional antibodies primarily directed toward the hem-
agglutinin that prevent infection of cells in tissue culture (re-
viewed in references 7 and 8). There are various forms of the MN
assay used in laboratories around the world, such as the 2-day
enzyme-linked immunosorbent assay (ELISA) protocol (8, 9),
3-day HA protocol (10), and 7-day HA protocol (11, 12). For the
purposes of seroepidemiology, the shorter protocols of 2 and 3
days are preferred. The 2- and 3-dayMN assays measure antibod-
ies to hemagglutinin and yet differ in theirmethods of preparation
of cell monolayers for infection as well as detection of virus infec-
tion. Cells are plated with the virus-serum mixture for the 2-day
MN assay, while a preformed cell monolayer is used for the 3-day
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MN assay. The 2-day MN assay detects nucleoprotein in infected
cells (9), while the 3-day assaymeasures hemagglutinating virus in
the culture medium or cytopathic effect (CPE) in the cell mono-
layer. Although there have been some direct comparisons between
serological assays performed bymultiple laboratories (12–15), the
impact of various MN assay protocols on the determination of
serological titers is unknown. Therefore, the aim of this study was
to assess the intralaboratory variability and sensitivity of the 2-day
ELISA MN assay and the 3-day HA MN assay for detecting anti-
bodies to A(H1N1)pdm09 virus and, as an extension, A(H3N2)
and A(H5N1) influenza viruses. The study was performed by the
CONSISE Laboratory Working Group members (see Acknowl-
edgments).
MATERIALS AND METHODS
Reagents used in the study. Laboratories were required to supply their
own reagents, virus stocks, MDCK cell lines, and appropriate cell culture
media for the study. Wild-type or reassortant viruses were used: the
A(H1N1)pdm09 strains were antigenically similar to the A/California/7/
2009 vaccine strain, and the A(H3N2) strains were antigenically similar to
the A/Perth/16/2009 or the A/Victoria/361/2011 vaccine strain. A repre-
sentative A(H5N1) virus from a clade that was recognized by the laborat-
ory’s serum panel was used. Serum panels contained approximately 10
test samples (sera or plasma), comprising low-, medium-, and high-titer
antibody levels. Sera were from seroepidemiology studies and vaccine
studies and from ferrets (to obtain high-titer serum in some laboratories)
and were supplied by each participating laboratory.
Development of consensus 2-day ELISA and 3-day MN protocols.
Parameters and variables for the 2-day ELISA (8) and the 3-day HA (10,
16) MN assays were listed. Laboratories within CONSISE shared their
protocols for either or both of the MN assays and listed their preferred
variables for each parameter identified.Datawere collected anonymously,
collated, and used to develop the consensus protocols.
Consensus 2-day ELISA and 3-day HAMN assays. The 2-day ELISA
MNassaywas to be performed as described in references 8 and 9, while the
3-dayHAMNassay was to be performed as described in references 10 and
16. Laboratories were required to use the specified parameters listed in the
CONSISE consensus protocols (Tables 1 and 2). Cell culture conditions
and the virus and serum panels used differed between laboratories. The
reciprocal of the highest dilution whereby 50% infection was prevented
was recorded as the titer for each serum sample.
Design of study—laboratory assay comparison. Individuals who
were members of CONSISE were invited to participate in the experimen-
tal laboratory comparative study. The researchers at 13 laboratories
agreed to participate, and each laboratory was assigned a code letter from
A to M (the order of assigned letters did not represent the order of the
listing of participants in Acknowledgments). Eleven laboratories (labora-
tories A to K) took part in the initial A(H1N1)pdm09 study, seven (labo-
ratories A, C, D, F, I, K, and L) in the A(H3N2) study, and three (labora-
tories H, L, and M) in the A(H5N1) study. Overall, 12 laboratories
(laboratories A to L) provided data that could be included in the analyses.
TABLE 1 CONSISE consensus 2-day ELISA MN assay for detecting antibodies to A(H1N1)pdm09 virusa
Parameter
Required
parameter Recommended parameter
Stock virus prepn
Cell substrate for virus growth Day 10 embryonated eggs
Stock virus infectivity concn and method of
determination
At least 106 TCID50/ml, read by ELISA
Stock storage Aliquots of bulk virus prepn
Serum prepn
Storage of sera following receipt 70°C,20°C, and 4°C, 1 or 2 freeze-thaw cycles in testing laboratory
Preassay treatment of sera Heat treatment at 56°C for 30 min, without dilution in media
Initial serum dilution 1:10
Sample type Sera only or plasma only
Virus prepn
Final virus amt per well 100 TCID50
Vol of virus solution added per sample 50 l
Virus/serum mix incubation 1 h at 37°C
Calculated starting serum dilution 1:10, excluding cell
culture vol
Cell prepn
Prepn of cells Cell suspension
Cell type used MDCK (“Salisbury”), MDCK-SIAT1
Assay diluent/culture medium Coon’s/Dulbecco’s modified Eagle’s medium with 1% BSA–FCS,
laboratory-preferred media
Assay setup
Incubation time of assay to endpoint reading 18–22 h
Incubation conditions 35–37°C, 5% CO2
No. of sample replicates Replicates preferred if available
Endpoint estimation
Endpoint determination Viral antigen detection by ELISA using antinucleoprotein antibody (clone)
Endpoint calculation method 50% neutralization
a Data are based on references 9 and 15. BSA, bovine serum albumin; FCS, fetal calf serum.
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Each laboratory was required to assay A(H1N1)pdm09, A(H3N2), or
A(H5N1) antibody levels in their panel of sera on at least three separate
occasions using the CONSISE protocols for both consensus MN assays:
the 2-day ELISA and the 3-day HA.
Statistical analysis. All analyses were based on the titers reported by
the participants. To enable comparison of assays for each laboratory, the
geometric mean titer (GMT) was calculated across runs and replicates to
give a single value for each sample for eachMNassaymethod. To calculate
the overall ratios between the assays for each laboratory, the ratio of the
3-day titer (detected by HA or CPE) to the 2-day ELISA MN titer was
calculated for each sample. The GMT was then calculated for all samples
in the serum panel for each laboratory. For the purpose of calculations,
negative titers reported as10 were assigned a value of 5, while high titers
reported as greater than or equal to a given value were assigned a value
corresponding to the next 2-fold titer; e.g., the value of 1,280 was as-
signed a value of 2,560. Correlations in results between assay methods for
the panels of serum samples were calculated using Spearman rank corre-
lations.
RESULTS
Development of consensus protocols for theMN assays.We as-
sessed the similarities between the methodologies used in 10 lab-
oratories for the 2-day ELISA and the 3-day HA MN assays. Pa-
rameterswere highly consistent between laboratories for the 2-day
ELISAMN assay method and closely followed publishedmethods
(8, 9). There was less consistency between the 3-day HAMN assay
methods, particularly in numbers of sample replicates performed
and determinations of the endpoint titer (50% or 100% neutral-
ization). There was variability in both assays with respect to cell
culture conditions (data not shown). To facilitate greater compa-
rability between laboratories, we developed consensus protocols
for the 2-day ELISA and 3-day HA MN assays by discussion and
agreement at CONSISE meetings (17) (Tables 1 and 2). Parame-
ters were classified as either required or recommended, based on
their importance in the interpretation of the assay titers. Required
parameters included serum dilutions and reporting of sample ti-
ters, assay incubation times, and endpoint calculation methods.
Recommended parameters listed appropriate variables for use.
Data received. (i) A(H1N1)pdm09 MN assays. Ten laborato-
ries returned data for both assays. ELISA was used for detection
for all 2-day MN assays. For the 3-day MN assay, 7 laboratories
used HA as the only detection method (turkey or guinea pig RBC
were used), 2 laboratories used CPE only, and 2 laboratories used
both HA and CPE detection methods. Both HA and CPE detec-
tion methods were assessed. Three laboratories used multiple ad-
ditional detection methods for one or both of the MN assays, but
TABLE 2 CONSISE consensus 3-day HA MN assay for detecting antibodies to A(H1N1)pdm09 virus
Parameter Required parameter Recommended parameter
Stock virus prepn
Cell substrates for virus growth Day 10 embryonated eggs, MDCK cells, MDCK-SIAT1 cells
Stock virus infectivity concn and method of
determination
At least 106 TCID50/ml, read by RBC agglutination
Stock storage Aliquots of bulk virus prepn
Serum prepn
Storage of sera following receipt 70°C,20°C, and 4°C, 1 or 2 freeze-thaw cycles in testing laboratory
Preassay treatment of sera Heat treatment at 56°C for 30 min, without dilution in media
Initial serum dilution 1:10
Sample type Sera only or plasma only
Virus prepn
Final virus amt per well 100 TCID50
Vol of virus solution added per sample/well 50 l, 100 l, or 200 l
Virus/serum mix incubation 1 h at 37°C
Virus/serum mix incubation on cell monolayer 1 h at 37°C
Calculated starting serum dilution 1:10, excluding
virus vol
Cell prepn
Prepn of cells Preformed monolayer
Cell types used MDCK (ATCC), MDCK (Salisbury), MDCK-SIAT1
Assay diluent Coon’s/Dulbecco’s modified Eagle’s medium, with trypsin (1/2 g/
ml), laboratory-preferred media
Cell infection media Coon’s/Dulbecco’s modified Eagle’s medium, with trypsin (1/2 g/
ml), laboratory-preferred media
Assay setup
Incubation time of assay to endpoint reading 3 days
Incubation conditions 35–37°C, 5% CO2
No. of sample replicates Replicates preferred if available
Endpoint estimation
Endpoint determination Turkey/guinea pig RBC agglutination, CPE
Endpoint calculation method 50% neutralization
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these data have not been included in the analysis. An eleventh
laboratory (laboratory K) did not perform the 2-day ELISA MN
assay and returned data for only the 3-day HA MN assay. This
laboratory shared a serum panel with laboratory F, which per-
formed both assays. The 3-day HA MN assay titers from labora-
tory K were compared with the 2-day ELISAMN assay titers from
laboratory F. Laboratories G and J performed each assay twice,
rather than three times; laboratory I performed the 3-day MN
assays twice.
(ii) A(H3N2)MN assays.Data were received from seven labo-
ratories. All laboratories used ELISA for detection in the 2-day
MN assay and HA (turkey or guinea pig RBC) for detection in the
3-dayHAMNassay, and two laboratories also sent corresponding
titers detected by CPE. Laboratory K performed only the 3-day
HA MN assay and shared a serum panel with laboratory F.
(iii) A(H5N1) MN assays. Data were received from three lab-
oratories. The results from laboratory M were negative for all of
the serum samples for all tests. No further analysis was possible for
this laboratory. Laboratories H and L used horse or goose RBC to
read out the 3-day HA MN assay.
Reproducibilitywithin laboratories: comparisonof replicate
tests. Laboratories performed an internal comparison of assay
protocols using their own serum panels. The titers within each
laboratory for each sample across replicate tests were compared.
Detecting antibodies to A(H1N1)pdm09 virus, there was good
reproducibility of the 2-day ELISA MN assays for the majority of
the laboratories, with titers fromover 80%of the laboratories with
replicate tests differing by2-fold, while laboratories B andDhad
10 to 30% of replicate titers differing by 2-fold (Fig. 1A). No
laboratories had titers from replicate tests differing by 4-fold
(Fig. 1B). For the 3-day MN assays, the variability differed de-
pending on the assay detection method. Using detection by HA,
four laboratories had replicates differing by4-fold, and yet this
was the case for only a very few samples (1 sample of 10 to 12
samples, 8.3 to 10%), while, using detection by CPE, two labora-
tories had titers from replicate tests differing by4-fold (2 sam-
ples of 10 [20%] and 7/12 samples [58%]) (Fig. 1B). Six laborato-
ries had titers from replicates differing by 2-fold by HA
detection (7.5 to 40%), while three laboratories had titers from
tests differing by 2-fold using detection by CPE (10 to 91.7%)
(Fig. 1A). Laboratory A showed high variability between replicates
using detection of the 3-dayMN titers by CPE (91.7%), as the data
from two replicate assays were comparable whereas the data from
the third assay were inconsistent (data not shown). In seven lab-
oratories (laboratories C, D, E, F, G, J, and K), there were no
replicates with results that differed by more than 2-fold.
For studies detecting antibodies to A(H3N2) and A(H5N1)
viruses, reproducibility was also good, with three instances of data
from replicates that differed by greater than 4-fold, though this
was the case for a small number of samples for each laboratory (10
to 20%). All other laboratories had data from replicates that dif-
fered by4-fold (Fig. 1C and D).
Relationship between 2-day ELISA MN assay and 3-day HA
and CPE MN assays for test serum panels. Titers for individual
test serum panels were compared for each laboratory between the
two assays. Comparing the titers obtained using the 2-day ELISA
and the 3-day HA MN assays for studies detecting antibodies to
A(H1N1)pdm09 virus (Fig. 2A), seven of the nine laboratories
had individual correlation coefficients that were above 0.9 (good)
and two of the nine laboratories did not (Table 3). Two laborato-
FIG 1 Reproducibility within laboratories of serology assay results for assays detecting antibodies to A(H1N1)pdm09 (A and B) and A(H3N2) and A(H5N1) (C
and D) viruses. Graphs show the (percent) proportions of replicate assays differing by2-fold (A and C) and4-fold (B and D) for the 2-day ELISAMN assay
and the 3-day MN assay with detection by HA and CPE for each participating laboratory for all sera. ND indicates instances in which the assay or detection
method was not performed.
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ries (G and H) had low correlation between the assays (0.580 and
0.638, respectively), as the 3-day MN HA assay gave narrow re-
sponse ranges compared to the 2-day ELISA MN assay. Compar-
ison of titers between the 2-day ELISA MN assay and the 3-day
MN assay detected by CPE showed higher overall consistency be-
tween the assays (Fig. 2B and Table 3).
The equivalent correlations were determined for comparisons
of assays detecting antibodies to A(H3N2) (Fig. 2C and D) and
FIG 2 Relationship between test sample titers for antibodies to A(H1N1)pdm09 (A and B), A(H3N2) (C and D), or A(H5N1) (E and F) viruses determined by
the 2-day ELISA MN assay and by the 3-day MN assay with detection by HA (A, C, and E) or CPE (B, D, and F). Each laboratory is represented by a color as
indicated in the key.
TABLE 3 Correlation of titers for test samples between assays by laboratorya
Laboratory
Correlation of 2-day MN to 3-day MN (Spearman rank correlation coefficient)
Preferred
assay(s)
A(H1N1)pdm09 A(H3N2) A(H5N1)
3-day HA 3-day CPE 3-day HA 3-day CPE 3-day HA 3-day CPE
A 0.966 0.901 0.865 2 day
B 0.976 2 day
C 0.992 0.966 3 day
D 0.892 0.890 0.898 3 day
E 0.944 2 day
F 0.965 0.966 3 day
G 0.580 2 day
H 0.638 0.738 0.883 0.908 2 day
I 0.970 0.954 0.901 2 day
J 0.944 3 day
Kb 0.931 0.942 3 day
L 0.439 0.833 Both
a For each laboratory, Spearman rank correlation coefficients were calculated to compare the 2-day ELISA MN data to the 3-day HA or CPE MN assay data.
b Data represent the 2-day ELISA MN assay titer data from laboratory F, as laboratories F and K shared serum panels.
Comparing MN Assay Methods
August 2015 Volume 22 Number 8 cvi.asm.org 961Clinical and Vaccine Immunology
 o
n
 February 19, 2019 by guest
http://cvi.asm
.org/
D
ow
nloaded from
 
A(H5N1) (Fig. 2E and F). For assays detecting antibodies to
A(H3N2) virus, the majority of laboratories obtained good corre-
lation between the 3-day HA and the 2-day ELISA MN assays
(range, 0.865 to 0.966) (Table 3). Laboratory L had a poor corre-
lation, with a coefficient of 0.439, as both of the assays gave a
narrow titer range (10 to 160) across the serum panel. There
were only two laboratories that had data detecting antibodies to
A(H5N1) virus, and they both showed reasonable correlation be-
tween the assays (Table 3). Laboratory L had much better corre-
lation with the assays detecting antibodies to A(H5N1) virus than
with those detecting antibodies to A(H3N2) virus.
Overall relationship between assays for each laboratory.The
ratio between the titers for the 2-day ELISA and 3-day MN assays
for the serum panels was calculated to assess whether a consistent
relationship between the performances of assays could be ob-
served for each laboratory (Table 4). Many of the ratios indicated
average titers within a 2-fold range for comparisons between
methods (i.e., ratios between 0.5 and 2.0), representing reasonable
agreement in assay sensitivity. For assays detecting antibodies to
A(H1N1)pdm09, laboratories F and G had lower 3-day HA MN
titers than 2-day ELISAMN titers. For laboratory G, the 3-dayHA
MN assay gave negative or low titers for all serum panel samples.
Laboratories I and K had 3-day MN titers that were much higher
than those measured for the 2-day ELISA MN assay. The ratios
between assays were different for the laboratories that also partic-
ipated in the comparison studies detecting antibodies toA(H3N2)
or A(H5N1). For the comparison of the assays detecting A(H3N2)
antibodies, laboratories D and K also had much higher 3-dayMN
assay titers than 2-day ELISA MN assay titers. For comparison of
assays detecting A(H5N1) antibodies, laboratory H had much
higher 3-day HA MN assay titers than 2-day ELISA MN assay
titers (Table 4).
Analysis for bias within the study. Potential factors for bias
were assessed. Although each laboratory had a preferredMNassay
(2-day ELISA, 3 day HA, or 3 day CPE, indicated in Table 3),
overall, this did not seem to affect the correlation between assays.
However, for laboratories where the titers from the two assays did
not correlate well [A(H1N1)pdm09 virus for laboratories G and
H; A(H3N2) virus for laboratory L] (Table 3), the 3-dayMN assay
showed less variation in titers (i.e., had less discriminating power)
(Fig. 2A and C, respectively). Yet there was also variability in the
correlations for different viruses within the same laboratory
(Table 3), indicating that this effect may be virus specific or due to
experience, as the studies were performed consecutively [the
A(H1N1)pdm09 assay was followed by the A(H3N2)/A(H5N1)
assay]. However, for laboratories with markedly different overall
titers in the comparisons of the assays (laboratories F, H, I, and K;
Table 4), there was no relationship between the preferred assay
and the titer achieved.Most laboratories used sera from adults (10
of 11) and wild-type influenza viruses (8 of 11); neither showed
any effect on assay comparability. The ratio of HA level to 50%
tissue culture infective dose (TCID50) for the virus stock from
each laboratory was assessed, and there was no clear relationship,
suggesting that there was no bias due to the presence of interfering
virus particles (HA titer range, 16 to 1,280 [median, 128]; log10
TCID50/ml range, 4.5 to 7 [median, 6]). Overall, therewas no clear
indication of major bias in the study.
DISCUSSION
Upon the emergence of a novel influenza virus, seroepidemiologi-
cal data are critical in understanding the spread and attack rate of
the virus to form the basis of pandemic risk and severity assess-
ments. Serology can also identify groups susceptible to infection
by a novel influenza virus in a population. Understanding the
impact of different MN assay protocols would strengthen these
estimates for policy decisions. Our comparison of MN assay
methodologies indicates that there is good correlation between
the 2-day ELISA and 3-day HA MN assays for detection of anti-
bodies to A(H1N1)pdm09 virus in most laboratories. These find-
ings were confirmed in an extension to this study performed with
A(H3N2) and A(H5N1) viruses. Overall, there is potential for
either assay to be used. Importantly, through participating in this
study, laboratories have aligned their methodology to the
CONSISE consensus assays described, harmonizing protocols in-
ternationally for the 2-day ELISA and 3-day HA MN assays.
Our intralaboratory assessment demonstrated that the results
from the 2-day ELISA and 3-day HA MN assays were largely re-
producible and comparable. The 2-day MN assay is read out by
ELISA using spectrophotometry, which is objective, while the
3-dayMN assay, which is read out by HA and CPE, requires more
experience and training. In addition, as our study required partic-
ipating laboratories to perform the assays on three separate occa-
sions, different preparations of RBC for the replicate 3-day HA
MN assays were likely. As a 2-fold range between titers for the
same sample is considered acceptable for serological studies, the
assays were overall highly reproducible on different days, with all
laboratories having 97% of samples with titers within a 4-fold
difference for the 2-day ELISA, 92% for the 3-day HA, and 92%
for the 3-day CPE MN assays.
Importantly, in over half of the laboratories, there was very
good correlation between the 2-day ELISA and 3-day HA MN
assays when a panel of sera was tested. This suggests that there is
no inherent difference in the results from the different assays,
despite their different readouts. Thus, there is no underlying sci-
entific reason that the differentMN assay formats cannot be com-
pared for detection of antibodies to A(H1N1)pdm09, A(H3N2),
or A(H5N1) viruses.
However, three laboratories did have poor correlation between
TABLE 4 Titer ratios between the 2-day ELISA MN assay and the 3-day
MN assay detected by HA and CPE
Laboratory
Avg ratio of 3-day MN titer to 2-day MN titer
A(H1N1)pdm09 A(H3N2) A(H5N1)
3-day
HA
3-day
CPE
3-day
HA
3-day
CPE
3-day
HA
3-day
CPE
A 2.4 1.5 1.9
B 0.9
C 0.8 1.5
D 2.0 3.7 3.8
E 1.0
F 0.3 1.3
G 0.1
H 1.5 1.6 5.8 6.3
I 5.22 0.88 0.87
J 1.2
K 2.4a 3.2
L 1.1 0.4
a Titer data for 2-day ELISA MN assay are from laboratory F, as laboratories F and K
shared serum panels.
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the assays, which may have been related to experience in, and
performance of, one particular method. Seven laboratories were
experienced in the 2-day ELISA MN assay before commencing
this study, and 6 laboratories were experienced in the 3-day HA
MN assay. Poor correlation between assays was more likely in
those laboratories inexperienced in performing the 3-dayHAMN
assay, indicating that training in HA or CPE readout might be
required. From the MN assay comparison performed here, we
anticipate that, as laboratories gain experience in both assays, the
correlation between the titers obtained for the 2-day ELISA and
3-day HA MN assays will improve. A mentoring system will be
established in subsequent international comparison studies per-
formed by CONSISE whereby personnel in laboratories who are
learning an assay will be assisted by local “experienced” laboratory
personnel. We anticipate that this collaborative assay develop-
ment will encourage rapid assay results and will result in data that
are more comparable between assays and laboratories in the fu-
ture.
It is notable that, although we were able to standardize many
assay-specific variables, such as virus concentration, incubation
times, serum dilution, and endpoint determination, in this study,
some factors were impossible to standardize. Cell culture condi-
tions are laboratory specific and may differ with respect to cell
lines, medium supplements, and incubation temperatures. Cell
culture conditions are often optimized for the variety of viruses
and experiments performed in a laboratory as well as for the avail-
ability of reagents and thus cannot be prescriptive.
A limitation of the present study is that the test serum panels
were not shared among all of the laboratories. As our study com-
pared assay protocols, rather than the performances of the differ-
ent laboratories, this is acceptable. Thus, the impact of using con-
sensus assay protocols on interlaboratory variability could not be
examined thoroughly. In a future study being planned by the
CONSISE Laboratory Working Group, shared serum panels will
be tested for antibodies to A(H1N1)pdm09 virus using consensus
2-day ELISA and 3-day MN assays and a consensus HI assay in
comparison with use of local assay protocols.
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